logo-loader
viewTissue Regenix Group PLC

Tissue Regenix chairman buys stock after 30% rise

drug_research_v2_350_528f0eacd96a7.jpg

The executive chairman of Tissue Regenix (LON:TRX) has bought £20,000 of shares in the company, whose share price has risen 30% in the last three months.

John Samuel snapped up 148,000 shares at 13.5p each, taking his stake in the regenerative tissue specialist to 3.7%.

Tissue Regenix’s technology uses animal or human tissue to replace damaged or worn out parts of the human body.

Its patented dCELL platform can be used to make 20-30 different products. The group's biggest focus is wound care, but it is also developing applications in the cardiac and orthopaedic markets.

The company is on track to launch its first product in the US in the first half of next year.

Tissue Regenix Woundcare, the firm’s US arm, has been recruiting heavily over the past year ahead of the launch of DermaPure, a skin repair product for chronic and acute wounds.

A processing agreement was signed in June with Community Tissue Services (CTS) to supply the tissue to be treated by dCell, while it is also close to appointing distributors.


Quick facts: Tissue Regenix Group PLC

Price: 1.1266 GBX

AIM:TRX
Market: AIM
Market Cap: £13.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Directorate Change

2 days, 20 hours ago

Holding(s) in Company

6 days, 20 hours ago

Holding(s) in Company

1 week, 1 day ago

Holding(s) in Company

1 week, 1 day ago

Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago

2 min read